Our interdisciplinary team of scientists collaborates to develop nanovaccines and nanotherapeutics
We are developing a universal influenza nanovaccine that would be effective against more strains of flu than current flu shots
For cancers, we are researching tumor-specific targets for nanotherapeutics
Nanovaccines can prevent tropical diseases such as malaria and filariasis
Nanotherapeutics use lower dosages than systemic drugs, allowing life-saving drugs to be used for young children
Nanoparticles can deliver therapeutic agents across the blood-brain barrier to treat neural disorders such as Alzheimer's, Parkinson's, and traumatic brain injury
Nanotechnologies can help optimize aging via improved biosensing capabilities and vaccine delivery
Researching veterinary diseases such as swine flu, avian flu, and bovine respiratory syncytial virus can help design nanovaccines to prevent similar diseases in humans
No needles, no boosters: extended-release nanovaccines can be delivered by nasal inhaler rather than injection
Nanovaccines don't need refrigeration (polio campaign worker in India carrying styrofoam cooler for vaccine)
Nanoparticles average only 300 nanometers in diameter, 1000 times smaller than the period at the end of a sentence.
Viral sequencing catches SARS-CoV2 mutations, guides effective public health response
Thousands of daily cases. Hundreds of thousands of deaths. Hundreds of millions of vaccine doses. As the tallies of COVID-19’s effects in the United States have mounted to a dizzying scale, a team … Read more
Iowa State researchers explain COVID-19 nanovaccine they’re developing
Iowa State researchers are closing in on a new kind of COVID-19 vaccine.
Pfizer and Moderna are both first generation COVID-19 vaccines.
"They're going to help us get through the pandemic, at … Read more & watch video
Engineers developing COVID-19 tests for mass production, mass distribution
Supported by more than $900,000 in federal grants, Iowa State University engineers are using their expertise in graphene-based biosensors to develop better, cheaper, quicker, more accessible testing … Read more
Iowa State’s Kanthasamy moving to University of Georgia
Nanovaccine Institute member Anumantha Kanthasamy, an internationally renowned researcher of Parkinson’s disease and related neurodegenerative disorders, has been appointed as the first University of … Read more